Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade

• Published in: Cancer immunology research Vol. 9; no. 11; p. 1316
• Main Authors: Aaboe Jørgensen, Mia, Ugel, Stefano, Linder Hübbe, Mie, Carretta, Marco, Perez-Penco, Maria, Weis-Banke, Stine Emilie, Martinenaite, Evelina, Kopp, Katharina, Chapellier, Marion, Adamo, Annalisa, De Sanctis, Francesco, Frusteri, Cristina, Iezzi, Manuela, Zocca, Mai-Britt, Hargbøll Madsen, Daniel, Wakatsuki Pedersen, Ayako, Bronte, Vincenzo, Andersen, Mads Hald
• Format: Journal Article
• Language: English
• Published: United States 01.11.2021
• Subjects: Animals; Arginase - metabolism; Cell Line, Tumor; Female; Humans; Mice; Myeloid Cells - metabolism; Neoplasms - drug therapy; Neoplasms - immunology; Tumor Microenvironment; Vaccines - pharmacology; Vaccines - therapeutic use; Xenograft Model Antitumor Assays

Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity of ARG1 promotes the formation of an immunosuppressive microenvironment and leads to a more aggressive phenotype in many cancers. I...